Search clinical trials for: Loncastuximab Tesirine and Durvalumab

Total 784 results

Baylor College of Medicine
Duke Cancer Institute

Not yet recruiting

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Mesothelioma

United States
Baki Topal
AstraZeneca

Active, not recruiting

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC)

Pancreatic Cancer Non-resectable

Belgium
National Cancer Institute, Naples
AstraZeneca; University of Campania "Luigi Vanvitelli"

Recruiting

A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5)

Carcinoma, Non-Small-Cell Lung

Italy
Institut Claudius Regaud
AstraZeneca

Active, not recruiting

A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI)

Glioblastoma

France
Syndax Pharmaceuticals

Completed

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Solid Tumor | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | Metastatic Tumor

United States
ModernaTX, Inc.
AstraZeneca

Active, not recruiting

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

United States, Israel, Australia
Moshe Ornstein

Completed

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca; Syndax Pharmaceuticals

Completed

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

United States
Trisha Wise-Draper
AstraZeneca

Active, not recruiting

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Metastatic Cancer | Recurrent Head and Neck Cancer

United States
Canadian Cancer Trials Group
National Health and Medical Research Council, Australia; Dutch Society of Physicians... and other collaborators

Active, not recruiting

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Non-Small Cell Lung Cancer

Canada, United States, France, Spain, Taiwan, China, Australia, Italy, Japan, Singapore, Korea, Republic of, New Zealand, Netherlands, Romania, Bulgaria, Brazil, Hungary, Poland, Ukraine
Eli Lilly and Company
AstraZeneca

Completed

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Solid Tumor

United States, Belgium, Israel, Czechia
Ulrich Keilholz
Charite University, Berlin, Germany; AstraZeneca

Completed

Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD)

Squamous Cell Carcinoma of the Head and Neck

Germany
University of Sydney
AstraZeneca; Australasian Lung Cancer Trials Group

Active, not recruiting

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. (ILLUMINATE)

EGFR Mutant Advanced Non Small Cell Lung Cancer

Taiwan, Australia
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Withdrawn

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Oropharynx Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Bladder Cancer | Carcinoma in Situ of Bladder

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; Marker Therapeutics, Inc.

Completed

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

United States
AstraZeneca

Completed

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Advanced Solid Tumors

Japan, Korea, Republic of, Taiwan
MedImmune LLC

Completed

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Germany, Spain, Canada, France, Korea, Republic of, Israel, Netherlands, United Kingdom
MedImmune LLC

Completed

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Select Advanced Solid Tumors

United States, France, Netherlands
British Columbia Cancer Agency
Ozmosis Research Inc.

Unknown

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Canada
University of Texas Southwestern Medical Center

Recruiting

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

Non Small Cell Lung Cancer

United States
Queen Mary University of London
AstraZeneca; Vall d'Hebron Institute of Oncology

Active, not recruiting

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)

Renal Clear Cell Carcinoma | Renal Papillary Cell Carcinoma

United Kingdom
MedImmune LLC

Completed

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, United Kingdom, France, Germany
Davendra Sohal

Recruiting

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Hepatocellular Carcinoma | Cirrhosis | Portal Hypertension

United States
University of Texas Southwestern Medical Center

Not yet recruiting

Durvalumab (MEDI4736) and Radiosurgery (fSRT vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Brain Metastases From Non-small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Oral Cancer | Larynx | Lip | Digestive Organs--Diseases

United States
Dana-Farber Cancer Institute
AstraZeneca

Suspended

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Mesothelioma

United States
Centre Leon Berard
Groupe Français de Pneumo-Cancérologie

Not yet recruiting

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum (FIRST-NEC)

Large Cell Neuroendocrine Carcinoma of the Lung

France
Canadian Cancer Trials Group
Canadian Cancer Clinical Trials Network; BC Cancer Foundation

Active, not recruiting

Prostate Cancer Biomarker Enrichment and Treatment Selection

Prostate Cancer

Canada
RenJi Hospital

Recruiting

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) (Dulect2020-1)

Liver Transplant; Complications | Liver Carcinoma

China
Kyowa Kirin, Inc.
AstraZeneca

Completed

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Advanced Solid Tumors

United States
Duke University
AstraZeneca

Completed

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA)

Triple Negative Breast Cancer

United States
Loren Mell, MD

Recruiting

QUantitative Assessment of Swallowing After Radiation (QUASAR) (QUASAR)

Head and Neck Cancer | Dysphagia | Oropharyngeal Dysphagia | Oropharynx Cancer | Oropharynx Squamous Cell Carcinoma

United States
Amgen

Recruiting

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Small-Cell Lung Cancer | Extensive-Stage Small-Cell Lung Cancer

United States, China, Japan, Switzerland, Turkey
Sidney Kimmel Comprehensive Cancer Center at Johns...
Fibrolamellar Cancer Foundation; Dracen Pharmaceuticals, Inc.

Recruiting

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Fibrolamellar Hepatocellular Carcinoma

United States
Instituto Portugues de Oncologia, Francisco Gentil...
AstraZeneca

Recruiting

Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy (IDEAR)

Non-small Cell Lung Cancer

Portugal
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Active, not recruiting

A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (CHORUS)

Non-small Cell Lung Cancer

United States
Brown University
Lifespan

Active, not recruiting

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung (358)

Stage III Non-small-cell Lung Cancer

United States
Case Comprehensive Cancer Center

Terminated

Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

Non-Small Cell Lung Cancer

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer

United States
University of Colorado, Denver
AstraZeneca

Withdrawn

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Pancreatic Cancer

United States
University of Maryland, Baltimore

Withdrawn

Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598) (Panc-Durval+RT)

Metastatic Pancreas Cancer
Institut für Klinische Krebsforschung IKF GmbH...
Hannover Medical School; AstraZeneca

Recruiting

Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

HCC | Hepatocellular Carcinoma Non-resectable

Germany
Azienda Ospedaliero-Universitaria Careggi

Not yet recruiting

Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)

Head and Neck Neoplasms
BeiGene

Terminated

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China, Taiwan, Australia, United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca; Brooklyn ImmunoTherapeutics, LLC

Active, not recruiting

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Paranasal Sinus Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

United States
MedImmune LLC

Completed

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NSCLC | Resectable | Early-stage

United States, Canada, Switzerland, Italy, France, Portugal, Spain
AstraZeneca

Active, not recruiting

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (OlympiaN)

Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Germany, Austria, Israel, Australia
Sheba Medical Center
Rambam Health Care Campus; AstraZeneca; Tel-Aviv Sourasky Medical Center

Recruiting

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung)

Metastatic or Locally Advanced NSCLC

Israel
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca

Recruiting

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Intrahepatic Cholangiocarcinoma

Germany

Search clinical trials for: Loncastuximab Tesirine and Durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations